Canada markets closed

Nuvo Pharmaceuticals Inc. (MRVFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7507+0.1287 (+20.69%)
At close: 10:27AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.6220
Open0.7507
BidN/A x N/A
AskN/A x N/A
Day's Range0.7507 - 0.7507
52 Week Range0.6200 - 1.4100
Volume2,450
Avg. Volume1,493
Market Cap8.574M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.9900
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to its Board of Directors

    MISSISSAUGA, Ontario, May 24, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Dale MacCandlish Weil to its Board of Directors (Board).

  • Business Wire

    Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders

    MISSISSAUGA, Ontario, May 16, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2022 Virtual Annual Meeting of Shareholders held on May 16, 2022 (the Meeting), all nominees listed in the management proxy circular dated April 8, 2022 were elected as directors of the Company.

  • Business Wire

    Miravo Healthcare™ Announces First Quarter 2022 Results

    MISSISSAUGA, Ontario, May 16, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2022. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements f